Related references
Note: Only part of the references are listed.Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window
Cristina Miglis et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae
Ching-Lung Lo et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2017)
Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis
Maged Muhammed et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-Analysis
Nikolaos Andreatos et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Randomized controlled trial of piperacillintazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum betalactamase-producing Escherichia coli
Yu Bin Seo et al.
BMC INFECTIOUS DISEASES (2017)
Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria
Ryan G. D'Angelo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Determining a clinical framework for use of cefepime and -lactam/-lactamase inhibitors in the treatment of infections caused by extended-spectrum--lactamase-producing Enterobacteriaceae
Hien M. Nguyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: MIC Matters
Nan-Yao Lee et al.
CLINICAL INFECTIOUS DISEASES (2013)
Evaluation of Clinical Outcomes in Patients with Bloodstream Infections Due to Gram-Negative Bacteria According to Carbapenem MIC Stratification
John S. Esterly et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli
Teena Chopra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Infections with Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae Changing Epidemiology and Drug Treatment Choices
Johann D. D. Pitout
DRUGS (2010)
Effect of Differences in MIC Values on Clinical Outcomes in Patients with Bloodstream Infections Caused by Gram-Negative Organisms Treated with Levofloxacin
Robyn DeFife et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Cephalosporin MIC Distribution of Extended-Spectrum-β-Lactamase- and pAmpC-Producing Escherichia coli and Klebsiella Species
Peggy C. Kohner et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Breakpoints for intravenously used cephalosporins in Enterobacteriaceae - EUCAST and CLSI breakpoints
G. Kahlmeter
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms
Sunil V. Bhat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Cefepime pharmacodynamics in patients with extended spectrum β-lactamase (ESBL) and non-ESBL infections
Su Young Lee et al.
JOURNAL OF INFECTION (2007)
Resistance in gram-negative bacteria: Enterobacteriaceae
David L. Paterson
AMERICAN JOURNAL OF MEDICINE (2006)
Extended-spectrum β-lactamases and clinical outcomes:: Current data
R Ramphal et al.
CLINICAL INFECTIOUS DISEASES (2006)
Influx of extended-spectrum β-lactamase producing enterobacteriaceae into the hospital
R Ben-Ami et al.
CLINICAL INFECTIOUS DISEASES (2006)
Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae:: Risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy
CI Kang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases:: Report from the ARREST program
PG Ambrose et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study
G Zanetti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime
A Wong-Beringer et al.
CLINICAL INFECTIOUS DISEASES (2002)
Activity of levofloxacin and ciprofloxacin against urinary pathogens
L Drago et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases:: Implications for the clinical microbiology laboratory
DL Paterson et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2001)
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia
DL Paterson et al.
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
